Lumbar Compression Fracture Medication

  • Author: Andrew L Sherman, MD, MS; Chief Editor: Rene Cailliet, MD   more...
 
Updated: Mar 25, 2010
 

Medication Summary

Oral medications are useful in patients with lumbar fractures for many reasons. The initial goal for most patients is pain relief. In geriatric patients, the goal of pain relief must be balanced by the potential adverse effects of some of the stronger pain medications. Often, the strongest pain medications can cause severe disorientation, respiratory depression, and constipation.

The second goal is to prevent further osteoporosis in these patients. A variety of agents may be used for this purpose, including parathyroid hormone, antiosteoporotic agents, bisphosphonates, and selective estrogen modulators.

Patients with spinal cord injuries need many different medications to assist with their rehabilitation and daily function (eg, to treat spasticity or autonomic dysreflexia).

Ohtori et al found that an L2 spinal nerve block may provide temporary relief of low back pain from acute osteoporotic lumbar vertebral fractures.[18] In a randomized, controlled study, 60 patients with acute L3 or L4 osteoporotic vertebral fractures received 1.5 mL of 1% lidocaine in a spinal nerve root block or a subcutaneous injection. Patients who received the L2 block showed greater improvement in pain relief, as measured by the visual analog scale score, at 1 hour, 1 week, and 2 weeks after treatment (P < .05). From 1 month to 4 months after treatment, however, significant pain-score differences between the groups no longer existed (P >.05). The authors concluded that, although L2 spinal nerve blocks had no long-term effects on pain and social function, they provided effective pain relief for 2 weeks.

Next

Analgesics

Class Summary

Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who have sustained fractures or other trauma.

Acetaminophen with codeine (Tylenol with codeine)

 

A centrally acting analgesic, often appropriate in elderly patients with moderate back pain.

Oxycodone (OxyContin, OxyIR, Roxicodone)

 

Reserved for patients with more severe back pain from their fracture; can be given in short- or long-acting form.

Acetaminophen (Tylenol, Panadol, Feverall)

 

DOC for pain in patients with documented hypersensitivity to aspirin or NSAIDs, with upper GI disease, or who are taking oral anticoagulants.

Tramadol hydrochloride (Ultram, Ultram ER)

 

Centrally acting analgesics. Although mode of action is not completely understood, from animal tests, at least 2 complementary mechanisms appear applicable: binding of parent and M1 metabolite to micro-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin.

Oxycodone and acetaminophen (Percocet)

 

Drug combination indicated for relief of moderate to severe pain.

Hydromorphone (Dilaudid)

 

Potent semisynthetic opiate agonist similar in structure to morphine. Approximately 7-8 times as potent as morphine on mg-to-mg basis with shorter or similar duration of action.

Fentanyl (Duragesic)

 

A synthetic opioid that is 75-200 times more potent with much shorter half-life than morphine sulfate. Has less hypotensive effects and is safer in patients with hyperactive airway disease than morphine because of minimal-to-no associated histamine release. By itself, it causes little cardiovascular compromise, although addition of benzodiazepines or other sedatives may result in decreased cardiac output and blood pressure.

Highly lipophilic and protein-bound. Prolonged exposure leads to accumulation in fat and delays weaning process.

Consider continuous infusion because of short half-life.

Parenteral form is DOC for conscious sedation analgesia. Ideal for analgesic action of short duration during anesthesia and during immediate postoperative period.

Excellent choice for pain management and sedation of short duration (30-60 min) and easy to titrate. Easily and quickly reversed by naloxone.

After initial parenteral dose, subsequent parenteral doses should not be titrated more frequently than q3h or q6h thereafter.

Transdermal form is used only for chronic pain conditions in opioid-tolerant patients. When using transdermal dosage form, most patients are controlled with 72-h dosing intervals; however, some require dosing intervals of 48 h.

Morphine sulfate (Roxanol, MSIR, MS Contin)

 

DOC for analgesia due to reliable and predictable effects, safety profile, and ease of reversibility with naloxone.

Various IV doses are used; commonly titrated until desired effect obtained.

Tramadol 37.5 mg /APAP 325 mg (Ultracet)

 

Centrally acting pain medication that combines tramadol hydrochloride with acetaminophen. Clinical trials demonstrated that the combination offers better pain relief over either medication alone. Indicated for the short-term (5 days or less) management of acute pain.

Previous
Next

Parathyroid hormones, recombinant

Class Summary

Promote new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity.

Teriparatide (Forteo)

 

Recombinant human parathyroid hormone rhPTH(1-34), which has identical sequence to 34 N-terminal amino acids (biologically active region) of 84-amino acid human parathyroid hormone. Acts as endogenous parathyroid hormone, thus regulating calcium and phosphate metabolism in bone and kidney. Works primarily to stimulate new bone by increasing number and activity of osteoblasts (bone-forming cells). Additional physiological actions include regulation of bone metabolism, renal tubular reabsorption of calcium and phosphate, and intestinal calcium absorption. When administered with calcium and vitamin D, teriparatide increases bone mineral density and decreases risk of fractures in patients with osteoporosis.

Previous
Next

Antiosteoporotic agents

Class Summary

Used to prevent worsening of osteoporosis and occasionally can reverse the process.

Calcitonin (Miacalcin, Osteocalcin)

 

Administered most often intranasally. Advantage is that it also can relieve some of the back pain associated with fracture.

Previous
Next

Bisphosphonates

Class Summary

Analogs of pyrophosphate that act by binding to hydroxyapatite in bone matrix, thereby inhibiting dissolution of crystals. Prevent osteoclast attachment to bone matrix and osteoclast recruitment and viability.

Alendronate (Fosamax)

 

A bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Patients should be upright and not lie down for 30 min after taking medication.

Previous
Next

Selective estrogen modulators

Class Summary

May act like estrogen to prevent bone resorption.

Raloxifene hydrochloride (Evista)

 

Selective estrogen receptor modulator that decreases bone loss.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Andrew L Sherman, MD, MS  Associate Professor of Clinical Rehabilitation Medicine, Vice Chairman, Chief of Spine and Musculoskeletal Services, Program Director, SCI Fellowship and PMR Residency Programs, Department of Rehabilitation Medicine, University of Miami, Leonard A Miller School of Medicine

Andrew L Sherman, MD, MS is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, American Medical Association, and Association of Academic Physiatrists

Disclosure: Pfizer Honoraria Speaking and teaching

Coauthor(s)

Nizam Razack, MD  FACS, JD, Assistant Professor of Neurological Surgery, Orthopedics, and Rehabilitation, University of Central Florida Medical School; Neurosurgeon, Spine and Brain Neurosurgery Center; Chairman, Department of Neurosurgery, Orlando Regional Medical Center

Nizam Razack, MD is a member of the following medical societies: American Association of Neurological Surgeons, American College of Surgeons, Congress of Neurological Surgeons, Florida Medical Association, and Society for Neuro-Oncology

Disclosure: Nothing to disclose.

Specialty Editor Board

Curtis W Slipman, MD  Director, University of Pennsylvania Spine Center; Associate Professor, Department of Physical Medicine and Rehabilitation, University of Pennsylvania Medical Center

Curtis W Slipman, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Association of Academic Physiatrists, International Association for the Study of Pain, and North American Spine Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Patrick M Foye, MD  Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain Service (Tailbone Pain Service: www.TailboneDoctor.com), University of Medicine and Dentistry of New Jersey, New Jersey Medical School

Patrick M Foye, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, Association of Academic Physiatrists, and International Spine Intervention Society

Disclosure: Nothing to disclose.

Kelly L Allen, MD  Medical Director, Medevals

Disclosure: Nothing to disclose.

Chief Editor

Rene Cailliet, MD  Professor-Chairman Emeritus, Department of Rehabilitation Medicine, University of Southern California School of Medicine; Former Director, Department of Rehabilitation Medicine, Santa Monica Hospital Medical Center

Rene Cailliet, MD is a member of the following medical societies: American Academy of Pain Medicine, American Academy of Physical Medicine and Rehabilitation, American Pain Society, Association of American Medical Colleges, International Association for the Study of Pain, and Pan American Medical Association

Disclosure: Nothing to disclose.

References
  1. Suh TT, Lyles KW. Osteoporosis considerations in the frail elderly. Curr Opin Rheumatol. Jul 2003;15(4):481-6. [Medline].

  2. Rapan S, Jovanovic S, Gulan G. Vertebroplasty for vertebral compression fracture. Coll Antropol. Sep 2009;33(3):911-4. [Medline].

  3. Sundaresan N, Rosen G, Boriani S. Primary malignant tumors of the spine. Orthop Clin North Am. Jan 2009;40(1):21-36, v. [Medline].

  4. Fast Facts on Osteoporosis. National Osteoporosis Foundation. Available at http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed May 26. 2009.

  5. Gibson JE, Pilgram TK, Gilula LA. Response of nonmidline pain to percutaneous vertebroplasty. AJR Am J Roentgenol. Oct 2006;187(4):869-72. [Medline]. [Full Text].

  6. American College of Radiology. ACR Appropriateness Criteria® osteoporosis and bone mineral density. National Guideline Clearinghouse. Available at http://guideline.gov/summary/summary.aspx?doc_id=11559. Accessed May 26, 2009.

  7. Bredella MA, Essary B, Torriani M, Ouellette HA, Palmer WE. Use of FDG-PET in differentiating benign from malignant compression fractures. Skeletal Radiol. May 2008;37(5):405-13. [Medline]. [Full Text].

  8. Hsieh PC, Koski TR, Sciubba DM, Moller DJ, O'Shaughnessy BA, Li KW, et al. Maximizing the potential of minimally invasive spine surgery in complex spinal disorders. Neurosurg Focus. 2008;25(2):E19. [Medline].

  9. Selznick LA, Shamji MF, Isaacs RE. Minimally invasive interbody fusion for revision lumbar surgery: technical feasibility and safety. J Spinal Disord Tech. May 2009;22(3):207-13. [Medline].

  10. Castellon AT, Meves R, Avanzi O. Intraoperative neurophysiologic spinal cord monitoring in thoracolumbar burst fractures. Spine (Phila Pa 1976). Nov 15 2009;34(24):2662-8. [Medline].

  11. Dalbayrak S, Onen MR, Yilmaz M, et al. Clinical and radiographic results of balloon kyphoplasty for treatment of vertebral body metastases and multiple myelomas. J Clin Neurosci. Feb 2010;17(2):219-24. [Medline].

  12. Layton KF, Thielen KR, Koch CA, Luetmer PH, Lane JI, Wald JT, et al. Vertebroplasty, first 1000 levels of a single center: evaluation of the outcomes and complications. AJNR Am J Neuroradiol. Apr 2007;28(4):683-9. [Medline]. [Full Text].

  13. Muijs SP, Nieuwenhuijse MJ, Van Erkel AR, Dijkstra PD. Percutaneous vertebroplasty for the treatment of osteoporotic vertebral compression fractures: evaluation after 36 months. J Bone Joint Surg Br. Mar 2009;91(3):379-84. [Medline].

  14. Lo YP, Chen WJ, Chen LH, Lai PL. New vertebral fracture after vertebroplasty. J Trauma. Dec 2008;65(6):1439-45. [Medline].

  15. Trout AT, Kallmes DF, Kaufmann TJ. New fractures after vertebroplasty: adjacent fractures occur significantly sooner. AJNR Am J Neuroradiol. Jan 2006;27(1):217-23. [Medline].

  16. Wardlaw D, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB, Ranstam J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet. Mar 21 2009;373(9668):1016-24. [Medline].

  17. Taylor RS, Fritzell P, Taylor RJ. Balloon kyphoplasty in the management of vertebral compression fractures: an updated systematic review and meta-analysis. Eur Spine J. Aug 2007;16(8):1085-100. [Medline]. [Full Text].

  18. [Best Evidence] Ohtori S, Yamashita M, Inoue G, et al. L2 spinal nerve-block effects on acute low back pain from osteoporotic vertebral fracture. J Pain. Aug 2009;10(8):870-5. [Medline].

  19. [Best Evidence] Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. Mar 23 2009;169(6):551-61. [Medline].

  20. O'Daly BJ, Morris SF, O'Rourke SK. Long-term functional outcome in pyogenic spinal infection. Spine. Apr 15 2008;33(8):E246-53. [Medline].

  21. Luzzati R, Giacomazzi D, Danzi MC, Tacconi L, Concia E, Vento S. Diagnosis, management and outcome of clinically- suspected spinal infection. J Infect. Apr 2009;58(4):259-65. [Medline].

  22. Benzel EC, Ball PA. Management of low lumbar fractures by dorsal decompression, fusion, and lumbosacral laminar distraction fixation. J Neurosurg. Apr 2000;92(2 Suppl):142-8. [Medline].

  23. Crandall D, Slaughter D, Hankins PJ, et al. Acute versus chronic vertebral compression fractures treated with kyphoplasty: early results. Spine J. Jul-Aug 2004;4(4):418-24.

  24. Dunnagan SA, Knox MF, Deaton CW. Osteoporotic compression fracture with persistent pain. Treatment with percutaneous vertebroplasty. J Ark Med Soc. Dec 1999;96(7):258-9. [Medline].

  25. Garfin SR, Yuan HA, Reiley MA. New technologies in spine: kyphoplasty and vertebroplasty for the treatment of painful osteoporotic compression fractures. Spine. Jul 15 2001;26(14):1511-5. [Medline].

  26. Harrington KD. Vertebral compression fractures: differentiation between benign and malignant causes. Iowa Orthop J. 1993;13:85-96.

  27. Hu SS, Capen DA, Rimoldi RL, Zigler JE. The effect of surgical decompression on neurologic outcome after lumbar fractures. Clin Orthop. Mar 1993;(288):166-73. [Medline].

  28. Kai MC, Anderson M, Lau EM. Exercise interventions: defusing the world's osteoporosis time bomb. Bull World Health Organ. 2003;81(11):827-30.

  29. Shaffrey CI, Shaffrey ME, Whitehill R, Nockels RP. Surgical treatment of thoracolumbar fractures. Neurosurg Clin N Am. Oct 1997;8(4):519-40. [Medline].

  30. Sinaki M, Wollan PC, Scott RW, Gelczer RK. Can strong back extensors prevent vertebral fractures in women with osteoporosis?. Mayo Clin Proc. Oct 1996;71(10):951-6. [Medline].

  31. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. May 24 2004;164(10):1108-12.

  32. Teng MM, Cheng H, Ho DM, Chang CY. Intraspinal leakage of bone cement after vertebroplasty: a report of 3 cases. AJNR Am J Neuroradiol. Jan 2006;27(1):224-9. [Medline].

  33. Viljakainen HT, Natri AM, Karkkainen M, et al. A positive dose-response effect of vitamin D supplementation on site-specific bone mineral augmentation in adolescent girls: a double-blinded randomized placebo-controlled 1-year intervention. J Bone Miner Res. Jun 2006;21(6):836-44.

  34. Von Feldt JM. Managing osteoporotic fractures: minimizing pain and disability. Rev Rhum Engl Ed. Jun 30 1997;64(6 Suppl):78S-80S. [Medline].

Previous
Next
 
Anteroposterior and lateral radiographs of an L1 osteoporotic wedge compression fracture.
Fluoroscopic view of a kyphoplasty procedure.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.